Myriad Genetics, Inc., (MYGN), a molecular diagnostic testing and precision medicine company, Tuesday announced that it has appointed Raj Jampa as its chief technology officer, effective June 1.
Before joining the diagnostic and precision medicine company, Jampa held senior technology leadership roles at Agilent Technologies, Exact Sciences and Genomic Health.
In pre-market activity, MYC+GN shares were trading at $4.19, down 2.10% on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.